Mechanisms underlying the J-curve for diastolic blood pressure: Subclinical myocardial injury and immune activation.

[1]  P. Whelton,et al.  Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control , 2018, Circulation.

[2]  A. Quyyumi,et al.  Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes. , 2017, Atherosclerosis.

[3]  Faisal Rahman,et al.  The J-shaped Curve for Blood Pressure and Cardiovascular Disease Risk: Historical Context and Recent Updates , 2017, Current Atherosclerosis Reports.

[4]  S. Yusuf,et al.  Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials , 2017, The Lancet.

[5]  J. Wojta,et al.  Soluble Urokinase-Type Plasminogen Activator Receptor Improves Risk Prediction in Patients With Chronic Heart Failure. , 2017, JACC. Heart failure.

[6]  D. Newby,et al.  High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease , 2016, Journal of the American College of Cardiology.

[7]  Deepak L. Bhatt,et al.  Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study , 2016, The Lancet.

[8]  J. Coresh,et al.  60 A comparison of HFrEF vs HFpEF’s clinical workload and cost in the first year following hospitalisation and enrollment in a disease management program , 2016, Journal of the American College of Cardiology.

[9]  C. Yuan,et al.  Blood Pressure Is a Major Modifiable Risk Factor Implicated in Pathogenesis of Intraplaque Hemorrhage: An In Vivo Magnetic Resonance Imaging Study , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[10]  Deepak L. Bhatt,et al.  Pulse Pressure and Risk for Cardiovascular Events in Patients With Atherothrombosis: From the REACH Registry. , 2016, Journal of the American College of Cardiology.

[11]  A. Kjær,et al.  Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV‐1‐infected patients: a nested case‐control study , 2015, HIV medicine.

[12]  A. Quyyumi,et al.  Soluble Urokinase Receptor and Chronic Kidney Disease. , 2015, The New England journal of medicine.

[13]  J. Jeppesen,et al.  suPAR: A New Biomarker for Cardiovascular Disease? , 2015, The Canadian journal of cardiology.

[14]  Christopher M O'Connor,et al.  Treatment of Hypertension in Patients With Coronary Artery Disease: A Scientific Statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. , 2015, Journal of the American College of Cardiology.

[15]  Christopher M O'Connor,et al.  Treatment of Hypertension in Patients With Coronary Artery Disease: A Scientific Statement From the American Heart Association, American College of Cardiology, and American Society of Hypertension , 2015, Hypertension.

[16]  A. Quyyumi,et al.  Soluble Urokinase Plasminogen Activator Receptor Level Is an Independent Predictor of the Presence and Severity of Coronary Artery Disease and of Future Adverse Events , 2014, Journal of the American Heart Association.

[17]  P. Greenland,et al.  Recommendations for treating hypertension: what are the right goals and purposes? , 2014, JAMA.

[18]  Jackson T. Wright,et al.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). , 2014, JAMA.

[19]  T. Hansen,et al.  CRP and suPAR are differently related to anthropometry and subclinical organ damage. , 2013, International journal of cardiology.

[20]  A. Quyyumi,et al.  Aggregate risk score based on markers of inflammation, cell stress, and coagulation is an independent predictor of adverse cardiovascular outcomes. , 2013, Journal of the American College of Cardiology.

[21]  S. Solomon,et al.  Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. , 2013, Journal of the American College of Cardiology.

[22]  M. Persson,et al.  Soluble Urokinase Plasminogen Activator Receptor is Associated With Inflammation in the Vulnerable Human Atherosclerotic Plaque , 2012, Stroke.

[23]  B. Fuhrman.  The urokinase system in the pathogenesis of atherosclerosis. , 2012, Atherosclerosis.

[24]  J. Vincent,et al.  suPAR as a prognostic biomarker in sepsis , 2012, BMC Medicine.

[25]  E. Ford.  Trends in Mortality From All Causes and Cardiovascular Disease Among Hypertensive and Nonhypertensive Adults in the United States , 2011, Circulation.

[26]  T. Hansen,et al.  Increased Plasma Soluble uPAR Level Is a Risk Marker of Respiratory Cancer in Initially Cancer-Free Individuals , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[27]  S. Bangalore,et al.  J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. , 2010, European heart journal.

[28]  T. Hansen,et al.  Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population , 2010, Journal of internal medicine.

[29]  G. Panjrath,et al.  The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? , 2009, Journal of the American College of Cardiology.

[30]  Carl J Pepine,et al.  Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. , 2009, European heart journal.

[31]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[32]  G. Mancia,et al.  Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous? , 2006, Annals of Internal Medicine.

[33]  G. Hansson.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.

[34]  Carl J Pepine,et al.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. , 2003, JAMA.

[35]  修 飯村,et al.  慢性糸球体腎炎患者に対するAngiotensin-Converting Enzyme InhibitorとAngiotensin II Receptor Blockerの併用による抗蛋白尿効果 , 2003 .

[36]  P. Ridker.  Clinical application of C-reactive protein for cardiovascular disease detection and prevention. , 2003, Circulation.

[37]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[38]  C. Mulrow,et al.  The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? , 1991, JAMA.

[39]  M. Marcus,et al.  The effect of hypertension and left ventricular hypertrophy on the lower range of coronary autoregulation. , 1988, Circulation.

[40]  R. Kerber,et al.  The effect of cardiac hypertrophy on the coronary collateral circulation. , 1985, Circulation.

[41]  WGAusten,et al.  A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association , 1975 .

[42]  R. Frye,et al.  A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. , 1975, Circulation.